SEC Form SC 13G/A filed by ImmunoPrecise Antibodies Ltd. (Amendment)
$IPA
Biotechnology: Pharmaceutical Preparations
Health Care
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G AMENDMENT NO. 1
INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
Immunoprecise Antibodies Ltd.
|
|
(Name of Issuer)
|
|
Common Shares, no par value |
|
(Title of Class of Securities)
|
|
45257F200
|
|
(CUSIP Number)
|
|
December 31, 2022
|
|
(Date of Event Which Requires Filing of This Statement)
|
Check the Appropriate box to designate the rule pursuant to which this schedule is filed:
Rule 13d-1(b)
X Rule 13d-1(c)
Rule 13d-1(d)
|
1
|
NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
|
||
|
Charmquark TWEE
|
|||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
(b) |
||
|
|
|||
|
3
|
SEC USE ONLY
|
||
|
|
|||
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
||
|
Belgium
|
|||
|
5
|
SOLE VOTING POWER
|
||
|
NUMBER OF
|
0
|
||
|
SHARES
|
6
|
SHARED VOTING POWER
|
|
|
BENEFICIALLY
|
1,565,865
|
||
|
OWNED BY
|
7
|
SOLE DISPOSITIVE POWER
|
|
|
EACH
|
0
|
||
|
REPORTING
|
8
|
SHARED DISPOSITIVE POWER
|
|
|
PERSON WITH
|
1,565,865
|
||
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
||
|
1,565,865
|
|||
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* q
|
||
|
|
|||
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
|
||
|
6.28%
|
|||
|
12
|
TYPE OF REPORTING PERSON*
|
||
|
CO
|
|||
*SEE INSTRUCTIONS BEFORE FILLING OUT!
|
1
|
NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
|
||
|
Charmquark EEN
|
|||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
(b) |
||
|
|
|||
|
3
|
SEC USE ONLY
|
||
|
|
|||
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
||
|
Belgium
|
|||
|
5
|
SOLE VOTING POWER
|
||
|
NUMBER OF
|
0
|
||
|
SHARES
|
6
|
SHARED VOTING POWER
|
|
|
BENEFICIALLY
|
1,565,865
|
||
|
OWNED BY
|
7
|
SOLE DISPOSITIVE POWER
|
|
|
EACH
|
0
|
||
|
REPORTING
|
8
|
SHARED DISPOSITIVE POWER
|
|
|
PERSON WITH
|
1,565,865
|
||
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
||
|
1,565,865
|
|||
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* q
|
||
|
|
|||
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
|
||
|
6.28%
|
|||
|
12
|
TYPE OF REPORTING PERSON*
|
||
|
CO
|
|||
Item 1 (a). Name of Issuer:
Immunoprecise Antibodies Ltd.
Item 1 (b). Address of Issuer’s Principal Executive Offices:
3204, 4464 Markham Street
Victoria, British Columbia V8Z 7X8
Canada
Victoria, British Columbia V8Z 7X8
Canada
Item 2 (a). Name of Person Filing:
|
i)
|
Charmquark TWEE
|
|
ii)
|
Charmquark EEN
|
Item 2 (b). Address of Principal Business Office or, if None, Residence:
Fabriekssfraat 7
Hamont-Achel
Belgium 3930
Belgium 3930
Item 2 (c). Citizenship:
Belgium
Item 2 (d). Title of Class of Securities:
Common Shares, no par value
Item 2 (e). CUSIP Number:
45257F200
| Item 3. |
If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
|
|
(a)
|
Broker or dealer registered under Section 15 of the Act;
|
| (b) |
Bank as defined in Section 3(a)(6) of the Act;
|
| (c) |
Insurance Company as defined in Section 3(a)(19) of the Act;
|
| (d) |
Investment Company registered under Section 8 of the Investment Company Act;
|
| (e) |
Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
|
| (f) |
Employee benefit plan or endowment plan in accordance with Rule 13d-1(b)(1)(ii)(F);
|
| (g) |
Parent holding company or control person, in accordance with Rule 13d-1(b)(1)(ii)(G);
|
| (h) |
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
|
|
(i)
|
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of
1940:
|
| (j) |
Group, in accordance with Rule 13d-1(b)(1)(ii)(j).
|
| X |
If this statement is filed pursuant to Rule 13d-1(c), check this box.
|
| Item 4. |
Ownership.
|
Provide the following information regarding the aggregate number and percentage of the class of securities identified in
Item 1.
| (a) |
Amount beneficially owned:
3,131,730 |
| (b) |
Percent of class:
|
12.56%*
*Based on 24,935,448 issued and outstanding shares of the Issuer as of November 10, 2022.
| (c) |
Number of shares as to which such person has:
|
|
(i)
|
Sole power to vote or to direct the vote:0
|
(ii) Shared power to vote or to direct the vote: 3,131,730
(iii) Sole power to dispose or to direct the disposition of: 0
(iv) Shared power to dispose or to direct the disposition of: 3,131,730
Instruction. For computations regarding securities which
represent a right to acquire an underlying security, see Rule 13d-3(d)(1).
| Item 5. |
Ownership of Five Percent or Less of a Class.
|
If the statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the class of securities, check the following [ ].
| Item 6. |
Ownership of More than Five Percent on Behalf of Another Person.
|
N/A
| Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
|
N/A
| Item 8. |
Identification and Classification of Members of the Group.
|
N/A
| Item 9. |
Notice of Dissolution of Group.
|
N/A
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of
or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
December 24_, 2023
|
|
|
(Date)
|
|
|
By: /s/ Dirk Van Hyfte
Dirk Van Hyfte, Director |
|
|
December 24, 2023
|
|
|
(Date)
|
|
|
By: /s/ Ingrid Brands
Ingrid Brands, Director
|